ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
entrectinib Sensitive: A1 - Approval
|
entrectinib Sensitive: A1 - Approval
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
ROS1 fusion
|
Melanoma
|
ROS1 fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
ROS1 fusion
|
Melanoma
|
ROS1 fusion
|
Melanoma
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
ROS1 fusion
|
Solid Tumor
|
ROS1 fusion
|
Solid Tumor
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
TPX-0005 Sensitive: C2 – Inclusion Criteria
|
TPX-0005 Sensitive: C2 – Inclusion Criteria
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
AB-106 Sensitive: C2 – Inclusion Criteria
|
AB-106 Sensitive: C2 – Inclusion Criteria
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
ensartinib Sensitive: C3 – Early Trials
|
ensartinib Sensitive: C3 – Early Trials
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
|
durvalumab Resistant: C3 – Early Trials
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
bevacizumab + crizotinib Sensitive: C4 – Case Studies
|
bevacizumab + crizotinib Sensitive: C4 – Case Studies
|
ROS1 fusion
|
GBM
|
ROS1 fusion
|
GBM
|
lorlatinib Sensitive: D – Preclinical
|
lorlatinib Sensitive: D – Preclinical
|
ROS1 fusion
|
Solid Tumor
|
ROS1 fusion
|
Solid Tumor
|
SIM1803-1A Sensitive: D – Preclinical
|
SIM1803-1A Sensitive: D – Preclinical
|